Coretox®
Muscle Spasticity
Medy-ToxPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Muscle Spasticity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Xeomin® Izmir Katip Celebi University | Phase 4 | BBB |
Baclofen Vanderbilt University | Phase 4 | BB |
Botox-A® The Catholic University of Korea | Phase 4 | BB |
Tizanidine Teva GTC | Phase 3 | BB |
INCOBOTULINUMTOXINA University Hospital, Toulouse | Phase 4 | BB |
View all 13 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →